{"groups":[{"description":"Patients who experience CRS/ICANS will receive this treatment\n\nSiltuximab: Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.","id":"FG000","title":"Siltuximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}